Long-term follow-up (5 years) showed no adverse effects on the liver, kidneys, nasal mucosa, etc. The results suggest that NASVAC immunotherapy is significantly safe and effective in suppressing HBV DNA and ALT, and in preventing the development of cirrhosis and HCC. Here, GPT is linked to hepatocellular carcinoma.